Department of Pharmacology and Therapeutics, McGill University, 3655 Sir William Osler Promenade, Room 1210, Montreal, Quebec, Canada.
Life Sci. 2012 Dec 10;91(23-24):1141-7. doi: 10.1016/j.lfs.2012.05.020. Epub 2012 Jun 13.
In this review we highlight the evidence for an intracellular origin of Abeta (Aβ) amyloid peptides as well as the observations for a pathological accumulation of these peptides in Alzheimer's disease and Down syndrome, as well as in transgenic animal models. We deliberate on the controversy as to whether the intracellular Aβ immunoreactive material is simply an accumulation of unprocessed full length amyloid precursor protein (APP) or a mix of processed APP fragments including Aβ. Finally, we discuss the possible pathological significance of these intracellular APP fragments and the expected future research directions regarding this thought-provoking problem.
在这篇综述中，我们强调了 Abeta（Aβ）淀粉样肽的细胞内起源的证据，以及这些肽在阿尔茨海默病和唐氏综合征以及转基因动物模型中病理性积累的观察结果。我们详细讨论了关于细胞内 Aβ免疫反应性物质是否仅仅是未加工全长淀粉样前体蛋白（APP）的积累还是包括 Aβ的加工 APP 片段的混合物的争议。最后，我们讨论了这些细胞内 APP 片段的可能病理意义以及关于这个发人深省的问题的预期未来研究方向。
